Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Gapping up/down: CYH +20%, VIPS +7%, LL +6% and WMT +3% after earnings; HSBC -6%, WAB -3% and CBRL -2% after earnings, DKS -1% after downgrade<p><strong>Gapping up<br/> In reaction to strong earnings/guidance</strong>:</p><ul><li><strong>CYH</strong> +20.3%, <strong>XCRA</strong> +11.6%, <strong>HLX</strong> +8%, <strong>EXAS</strong> +7.2%, <strong>VIPS</strong> +6.9%, <strong>LL</strong> +6.1%, <strong>EROS</strong> +5.6%, <strong>OPME</strong> +3.6%</li><li><strong>MDR</strong> +3.3%, <strong>WMT</strong> +3.2%, <strong>CTG</strong> +3%, <strong>AAP</strong> +2.4%, <strong>MDWD</strong> +2.4%, <strong>CYRN</strong> +2.3%, <strong>NRZ</strong> +2%, <strong>M</strong> +1.9%, <strong>NDSN</strong> +1.7%, <strong>HD</strong> +1.7%, <strong>EXPD</strong> +0.9%, <strong>WLK</strong> +0.6%</li></ul><p><br/> <strong>M&A news</strong>:</p><ul><li><strong>DGAS</strong> +16.6% (enters into a definitive agreement to merge with an affiliate of Peoples Natural Gas; Delta shareholders will receive $30.50 in cash/share)</li><li><strong>PLKI</strong> +16.4% (Restaurant Brands (QSR) is in advanced discussions to purchase PLKI, according to Bloomberg)</li><li><strong>FCH</strong> +15.8% (Ashford Hospitality Trust (AHT) submits non-binding proposal to acquire FelCor for a total consideration of $9.27 per share)</li><li><strong>TROX</strong> +14.4% (to acquire the TiO2 business of Cristal for $1.673 bln of cash and Class A ordinary shares)</li></ul><p><strong>Select metals/mining stocks trading higher</strong>: <strong>CLF</strong> +2.9%, <strong>AKS</strong> +2.5%, <strong>X</strong> +1.5%, <strong>MT</strong> +1.3%, <strong>HBM</strong> +1.2%, <strong>AUY</strong> +0.8%, .<br/> <br/> <strong>Other news</strong>:</p><ul><li><strong>DCTH</strong> +46.3% (study demonstrated that 45.7% of patients with ocular melanoma that metastasized to the liver who underwent percutaneous hepatic perfusion using investigational Melphalan/HDS experienced a complete or partial response)</li><li><strong>EYEG</strong> +34.1% (enters into exclusive, worldwide licensing agreement with Valeant Pharmaceuticals (VRX))</li><li><strong>APOP</strong> +20.1% (announces 'positive' final results from its clinical trial of ApoGraft in healthy donors)</li><li><strong>IDXG</strong> +19.5% (announces the initiation of a collaborative research program with Viatar CTC Solutions to detect and characterize early cancer in liquid biopsies)</li><li><strong>VCEL</strong> +8.2% (FDA has designated the investigation of ixmyelocel-T for reduction in the risk of death and cardiovascular hospitalization in patients with chronic advanced heart failure due to ischemic dilated cardiomyopathy as a Fast Track Development Program)</li><li><strong>VALE</strong> +7.6% (new shareholders' agreement was filed, executed by Litel Participações S.A., Litela Participações S.A., Bradespar S.A., Mitsui & Co., and BNDES Participações </li><li><strong>RBS</strong> +5.4% (provides update on remaining State Aid obligation)</li><li><strong>EW</strong> +5.3% (CardiAQ testing has been completed; enrollment has resumed )</li><li><strong>BCLI</strong> +4.2% (signs an agreement w/ CCRM to support the market authorization request for NurOwn)</li><li><strong>PGH</strong> +3.1% (announcs plan to reduce its outstanding debt through the use of $530 mln cash on hand)</li><li><strong>MDLZ</strong> +2.6% (following confirmation that KHC withdrew transaction with UL/UN)</li><li><strong>GRPN</strong> +1.9% (continued strength)</li><li><strong>SRPT</strong> +1.8% (enters into an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $125 million)</li><li><strong>AEHR</strong> +1.5% (receives an order in excess of $4 mln from a subcontractor to its lead customer for the FOX-XP Test and Burn-in System)</li><li><strong>SCON</strong> +1.4% (receives a U.S. Patent for an aspect of the RCE-CDR system architecture used in manufacturing Conductus HTS wire)</li><li><strong>GIS</strong> +1.3% (following confirmation that KHC withdrew transaction with UL/UN)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>JAG</strong> +3.7% (initiated with a Outperform at Credit Suisse)</li><li><strong>SBLK</strong> +3.1% (upgraded to Buy from Hold at Deutsche Bank)</li><li><strong>ADNT</strong> +1.3% (initiated with a Overweight at Morgan Stanley)</li></ul><p><strong>Gapping down<br/> In reaction to disappointing earnings/guidance</strong>:</p><ul><li><strong>DAKT</strong> -25.8%, <strong>MNTA</strong> -18.4%, <strong>HSBC</strong> -6.2%, <strong>DDS</strong> -4.9%, <strong>CYOU</strong> -4.2%, <strong>AMRI</strong> -3.5%, <strong>SOHU</strong> -3.2%, <strong>WAB</strong> -3%, <strong>MGIC</strong> -2.6%, <strong>UIHC</strong> -2.5%</li><li><strong>CBRL</strong> -1.6%, <strong>AU</strong> -1.3%, <strong>PWR</strong> -1.2%, <strong>CRMT</strong> -0.6%</li></ul><p><strong>M&A news</strong>:</p><ul><li><strong>UL</strong> -8.5% (Unilever and Kraft Heinz (KHC) jointly confirm that KHC has amicably agreed to withdraw its proposal for a combination of the two companies )</li><li><strong>UN</strong> -8.3%, <strong>KHC</strong> -5% </li></ul><p><strong>Other news</strong>:</p><ul><li><strong>TRVN</strong> -33.4% (announces its Phase 3 APOLLO-1 and APOLLO-2 pivotal efficacy studies of oliceridine)</li><li><strong>CDTX</strong> -32.6% (reports that the Phase 2 RADIANT clinical trial in acute vulvovaginal candidiasi did not show sufficient efficacy to justify further development)</li><li><strong>MNTA</strong> -18.9% (receives notice of warning letter from FDA to contracted Glatopa; Approval of the Glatopa 40 mg ANDA will be dependent on resolution of Pfizer (PFE) facility compliance issues)</li><li><strong>DRYS</strong> -18.8% (enters into $200 mln stock purchase agreement with Kalani Investments)</li><li><strong>IMMU</strong> -3.4% (files a federal lawsuit and a motion seeking injunctive relief against venBio Select Advisor and venBio's four director candidates)</li><li><strong>GMS</strong> -3.1% (commences 6 mln common stock offering by its existing stockholders, including certain affiliates of AEA Investors LP)</li><li><strong>ING</strong> -1.1% (in sympathy with HSBC earnings)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>FCX</strong> -3.7% (downgraded to Sell from Hold at Deutsche Bank)</li><li><strong>EIGI</strong> -3.2% (downgraded to Underweight from Equal-Weight at Morgan Stanley)</li><li><strong>DKS</strong> -1.1% (downgraded to Perform from Outperform at Oppenheimer)</li><li><strong>OHI</strong> -0.9% (downgraded to Hold from Buy at Jefferies)</li><li><strong>BLMN</strong> -0.8% (downgraded to Neutral from Overweight at JP Morgan)</li></ul></td> </tr></table>"